Our Purpose
About
Science & Medicine
News and Press
Company Statements
Gilead Sciences Statement on Remdesivir Clinical Data
Gilead Sciences Response to U.S. Senators on Trial Diversity
Gilead Sciences Statement on NEJM Publication of Remdesivir Data From NIAID Study
Gilead Sciences Statement on Expanding Global Supply of Investigational Antiviral Remdesivir
Gilead Statement on Complaint Against Federal Government in The Court of Federal Claims
Gilead Sciences Statement on Data From Remdesivir Study in Patients With Severe COVID-19 in China
Gilead Sciences Response to Médecins Sans Frontières
Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation
Gilead Sciences Statement on Ensuring Continued Supply of HIV Medicine Amid Coronavirus Outbreak
Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials
Gilead Statement on U.S. Government Complaint Regarding HIV PrEP and PEP Patents
Petitions to US Patent and Trademark Office on HIV PrEP Patents
HIV Medicines Reach 10 Million People
Discover Study Of FTAF For PrEP
Corporate Responsibility Report 2015
Gilead Supports PrEP Education
Corporate Contributions Report